BCG Vaccine

"BCG Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.

Descriptor ID	D001500
MeSH Number(s)	D20.215.894.135.825.100
Concept/Terms	BCG Vaccine BCG Vaccine Vaccine, BCG Bacillus Calmette Guerin Vaccine Calmette Guerin Bacillus Vaccine Calmette's Vaccine Calmette Vaccine Calmettes Vaccine Vaccine, Calmette's

Below are MeSH descriptors whose meaning is more general than "BCG Vaccine".

Chemicals and Drugs [D]
Complex Mixtures [D20]
Biological Products [D20.215]
Vaccines [D20.215.894]
Bacterial Vaccines [D20.215.894.135]
Tuberculosis Vaccines [D20.215.894.135.825]
BCG Vaccine [D20.215.894.135.825.100]

Below are MeSH descriptors whose meaning is related to "BCG Vaccine".

Below are MeSH descriptors whose meaning is more specific than "BCG Vaccine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "BCG Vaccine" by people in this website by year, and whether "BCG Vaccine" was a major or minor topic of these publications.

Bar chart showing 23 publications over 13 distinct years, with a maximum of 4 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2006	1	0	1
2008	1	1	2
2011	0	1	1
2012	0	2	2
2014	1	0	1
2017	0	1	1
2019	2	0	2
2020	2	0	2
2021	2	1	3
2022	0	1	1
2023	0	2	2
2024	2	2	4

Below are the most recent publications written about "BCG Vaccine" by people in Profiles.

Necchi A, Roumigui? M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 06; 25(6):720-730.

View in: PubMed
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 07; 212(1):74-86.

View in: PubMed
Moussa M, Abou Chakra M, Shore ND, Papatsoris A, Farahat Y, O'Donnell MA. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists. Arch Ital Urol Androl. 2024 Mar 19; 96(1):12244.

View in: PubMed
Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Gu?rin for patients with Bacillus Calmette-Gu?rin-na?ve high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024 May; 20(14):891-901.

View in: PubMed
Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.

View in: PubMed
Abou Chakra M, Shore ND, Dillon R, O'Donnell MA. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Gu?rin-Unresponsive and Bacillus Calmette-Gu?rin-Exposed Nonmuscle-Invasive Bladder Cancer. Urol Pract. 2024 01; 11(1):97-107.

View in: PubMed
Kates M, Mansour AM, Lamm DL, Shore N, Maulhardt H, Wendt A, Verco J, Marin A, Dewnani K, Verco S, diZerega GS. Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. J Urol. 2022 10; 208(4):821-829.

View in: PubMed
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Yl?-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.

View in: PubMed
Jain M, Vadboncoeur J, Garg SJ, Biswas J. Bacille Calmette-Gu?rin: An ophthalmic perspective. Surv Ophthalmol. 2022 Mar-Apr; 67(2):307-320.

View in: PubMed
Shore ND, Palou Redorta J, Robert G, Hutson TE, Cesari R, Hariharan S, Rodr?guez Faba ?, Briganti A, Steinberg GD. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol. 2021 10; 39(10):642-663.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement